Autologous Transplantation for Chronic Myelogenous Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

December 31, 2007

Study Completion Date

October 31, 2009

Conditions
Chronic Myelogenous Leukemia
Interventions
DRUG

Busulfan

130 mg/m\^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)

DRUG

Cyclophosphamide

60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)

DRUG

Imatinib Mesylate

Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is \>1500/mcl and platelets \>50,000 /mcl, may be titrated to maintain ANC \>1.0 and platelets \>50,000 /mcl.

PROCEDURE

Autologous Stem Cell Transplantation

Stem Cell Infusion: Unpurged hematopoietic stem cells administered intravenously on day 0.

Trial Locations (1)

77070

UT MD Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER

NCT01003054 - Autologous Transplantation for Chronic Myelogenous Leukemia | Biotech Hunter | Biotech Hunter